Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Journal Article (Journal Article;Review;Systematic Review)

Eosinophilic esophagitis (EoE) is a clinicopathologic condition of increasing recognition and prevalence. In 2007, a consensus recommendation provided clinical and histopathologic guidance for the diagnosis and treatment of EoE; however, only a minority of physicians use the 2007 guidelines, which require fulfillment of both histologic and clinical features. Since 2007, the number of EoE publications has doubled, providing new disease insight. Accordingly, a panel of 33 physicians with expertise in pediatric and adult allergy/immunology, gastroenterology, and pathology conducted a systematic review of the EoE literature (since September 2006) using electronic databases. Based on the literature review and expertise of the panel, information and recommendations were provided in each of the following areas of EoE: diagnostics, genetics, allergy testing, therapeutics, and disease complications. Because accumulating animal and human data have provided evidence that EoE appears to be an antigen-driven immunologic process that involves multiple pathogenic pathways, a new conceptual definition is proposed highlighting that EoE represents a chronic, immune/antigen-mediated disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. The diagnostic guidelines continue to define EoE as an isolated chronic disorder of the esophagus diagnosed by the need of both clinical and pathologic features. Patients commonly have high rates of concurrent allergic diatheses, especially food sensitization, compared with the general population. Proved therapeutic options include chronic dietary elimination, topical corticosteroids, and esophageal dilation. Important additions since 2007 include genetic underpinnings that implicate EoE susceptibility caused by polymorphisms in the thymic stromal lymphopoietin protein gene and the description of a new potential disease phenotype, proton pump inhibitor-responsive esophageal eosinophila. Further advances and controversies regarding diagnostic methods, surrogate disease markers, allergy testing, and treatment approaches are discussed.

Full Text

Duke Authors

Cited Authors

  • Liacouras, CA; Furuta, GT; Hirano, I; Atkins, D; Attwood, SE; Bonis, PA; Burks, AW; Chehade, M; Collins, MH; Dellon, ES; Dohil, R; Falk, GW; Gonsalves, N; Gupta, SK; Katzka, DA; Lucendo, AJ; Markowitz, JE; Noel, RJ; Odze, RD; Putnam, PE; Richter, JE; Romero, Y; Ruchelli, E; Sampson, HA; Schoepfer, A; Shaheen, NJ; Sicherer, SH; Spechler, S; Spergel, JM; Straumann, A; Wershil, BK; Rothenberg, ME; Aceves, SS

Published Date

  • July 2011

Published In

Volume / Issue

  • 128 / 1

Start / End Page

  • 3 - 20.e6

PubMed ID

  • 21477849

Electronic International Standard Serial Number (EISSN)

  • 1097-6825

Digital Object Identifier (DOI)

  • 10.1016/j.jaci.2011.02.040


  • eng

Conference Location

  • United States